StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$4.96−0.04 (-0.80%)

Close on Nov 17, 2026Market cap $193.13MP/E –Yield –

Entrada Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Entrada Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$176.53M. For fiscal 2025 it was -$157.90M, down 435.9% from the year before. The highest annual figure on record is $47.01M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$157.90M-435.9%
FY2024Dec 31, 2024$47.01M–
FY2023Dec 31, 2023-$3.16M–
FY2022Dec 31, 2022-$97.25M–
FY2021Dec 31, 2021-$51.13M–
FY2020Dec 31, 2020-$26.67M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.96M–
Q1 FY2026Mar 31, 2026-$42.30M–
Q4 FY2025Dec 31, 2025-$42.21M–
Q3 FY2025Sep 30, 2025-$47.05M–
Q2 FY2025Jun 30, 2025-$46.85M-187.7%
Q1 FY2025Mar 31, 2025-$21.79M-203.2%
Q4 FY2024Dec 31, 2024-$5.87M-219.6%
Q3 FY2024Sep 30, 2024-$21.66M-254.6%
Q2 FY2024Jun 30, 2024$53.42M–
Q1 FY2024Mar 31, 2024$21.11M–
Q4 FY2023Dec 31, 2023$4.91M–
Q3 FY2023Sep 30, 2023$14.01M–
Q2 FY2023Jun 30, 2023-$16.30M–
Q1 FY2023Mar 31, 2023-$5.78M–
Q4 FY2022Dec 31, 2022-$25.58M–
Q3 FY2022Sep 30, 2022-$25.94M–
Q2 FY2022Jun 30, 2022-$23.58M–
Q1 FY2022Mar 31, 2022-$22.15M–
Q4 FY2021Dec 31, 2021-$18.46M–
Q3 FY2021Sep 30, 2021-$14.36M–
Q2 FY2021Jun 30, 2021-$9.91M–
Q1 FY2021Mar 31, 2021-$8.39M–
Q4 FY2020Dec 31, 2020-$8.65M–
Q3 FY2020Sep 30, 2020-$6.97M–

More Entrada Therapeutics figures

See a number that looks wrong?